Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04141 (granulocyte-macrophage colony-stimulating factor)
 6,790 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In this report, we showed for the first time that granulocyte-macrophage colony-stimulating factor plasma levels are elevated in patients with severe heart failure, and these levels are correlated well with neurohormonal activation and hemodynamic deterioration characterizing this syndrome.
Am J Cardiol 2000 Sep 15
PMID:Clinical and neurohormonal correlates of circulating granulocyte-macrophage colony-stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1098 Feb 34

The present study investigates the differences in serum activity of granulocyte-macrophage colony-stimulating factor, macrophage chemoattractant protein-1, and macrophage inflammatory protein-1alpha between hypertensive patients with and without significant hyperlipidemia before receiving any medical treatment. The serum activity of the studied inflammatory factors is more elevated in hypertensive patients with significant hyperlipidemia and may be associated with atherosclerotic inflammatory process induced by the coexistence of 2 major cardiovascular risk factors.
Am J Cardiol 2000 Mar 15
PMID:Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. 1200 61

Hematopoietic cytokines, traditionally known to influence cellular proliferation, differentiation, maturation, and lineage commitment in the bone marrow, include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, stem cell factor, Flt-3 ligand, and erythropoietin among others. Emerging evidence suggests that these cytokines also exert multifarious biological effects on diverse nonhematopoietic organs and tissues. Although the precise mechanisms remain unclear, numerous studies in animal models of myocardial infarction (MI) and heart failure indicate that hematopoietic cytokines confer potent cardiovascular benefits, possibly through mobilization and subsequent homing of bone marrow-derived cells into the infarcted heart with consequent induction of myocardial repair involving multifarious mechanisms. In addition, these cytokines are also known to exert direct cytoprotective effects. However, results from small-scale clinical trials of G-CSF therapy as a single agent after acute MI have been discordant and largely disappointing. It is likely that cardiac repair following cytokine therapy depends on a number of known and unknown variables, and further experimental and clinical studies are certainly warranted to accurately determine the true therapeutic potential of such therapy. In this review, we discuss the biological features of several key hematopoietic cytokines and present the basic and clinical evidence pertaining to cardiac repair with hematopoietic cytokine therapy.
Basic Res Cardiol 2011 Sep
PMID:Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. 2154 7

In spite of novel pharmacological and reperfusion strategies, many patients with acute myocardial infarction (AMI) and critical limb ischemia (CLI) due to peripheral arterial disease (PAD) have an unfavorable prognosis. Recent studies suggest that bone marrow cell mobilization with granulocyte colony-stimulating factor (GCSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) may have a beneficial effect in AMI and CLI, likely due to endothelial progenitor cell-mediated angiogenesis and enhanced blood flow to the ischemic tissues. However, controversy still exists because published studies evaluated the effect of bone marrow cell mobilization in different patient populations, timing for drug administration in relationship to the acute event and to the reperfusion procedure differed, clinical endpoints and the techniques used for assessing cardiac function and volumes were not the same. Nevertheless, these small clinical studies provided useful information that helped design large phase III clinical trials and, ultimately, will establish whether bone marrow cell mobilization can have a role in AMI and CLI treatment.
G Ital Cardiol (Rome) 2014 Sep
PMID:[Role of G-CSF and GM-CSF therapy in patients with acute myocardial infarction and critical limb ischemia]. 2529 55